Alzheimer's Disease Viewed as a Neurovascular Inflammatory Disorder
阿尔茨海默病被视为一种神经血管炎症性疾病
基本信息
- 批准号:9195011
- 负责人:
- 金额:$ 1.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-12-06 至 2017-12-05
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAcademyAddressAgeAlzheimer&aposs DiseaseAmyloidAnimal ModelAreaAwards and PrizesBasic ScienceBiological MarkersBiologyBlood - brain barrier anatomyBlood VesselsBrainCerebral Amyloid AngiopathyCerebrovascular DisordersChild CareClinicalClinical SciencesClinical TrialsCollaborationsCommunicationCommunitiesDataDementiaDeveloping CountriesDevelopmentDisabled PersonsDiseaseDisease ProgressionEnsureEnvironmentEtiologyEventFacultyFamilyFellowshipFemaleFosteringFoundationsFunctional disorderFutureGeneticGoalsGovernmentHeadHealthHealthcare SystemsHumanImageImmune responseImpaired cognitionImpairmentIndustryInflammationInflammatoryInternationalKnowledgeLabelLifeLinkMapsMedical ResearchMicrovascular DysfunctionMolecularMolecular TargetMonitorNational Institute of Neurological Disorders and StrokeNeurodegenerative DisordersNeuronsNew YorkNonprofit OrganizationsOnset of illnessOralParticipantPathologyPatientsPersonsPhysiological ProcessesPopulationPreventionPrizeProcessPublicationsPublishingResearchResearch PersonnelRisk FactorsRoleScienceStrokeStudy modelsTechnologyTestingTranslatingTranslationsTravelUnderrepresented MinorityUpdateVascular DementiaVascular DiseasesWomanWorkabstractingaging populationbasebiomarker identificationcareerdata exchangediscounteffective therapygenetic informationglobal healthhealth economicsimprovedinsightinterdisciplinary approachknowledge basemeetingsminority investigatorneuropathologyneurovascularnew therapeutic targetnovelpatient populationposterspre-clinicalpreventracial minorityrepositorysocioeconomicssymposiumtherapeutic targettoolvascular contributionsvascular inflammationwebinar
项目摘要
Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder
PROJECT SUMMARY / ABSTRACT
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder lacking effective treatments. Most
clinical trials testing the long-standing amyloid hypothesis of AD have shown little promise. The future of novel
treatments targeting other pathophysiological processes in the disease is uncertain. Growing evidence
supports a role for neurovascular inflammation as a major causative or exacerbating factor in AD onset and
progression. However, the scientific community has yet to label AD a vascular disease and questions remain
about the viability of neurovascular inflammation as a potential therapeutic target. To address this controversy
head-on, the New York Academy of Sciences will present a 1-day symposium and simulcast Webinar,
“Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder” on 12/6/2016. The goal of this
symposium is to evaluate clinical and preclinical data investigating the role of neurovascular pathology in the
development of AD. Critical barriers to understanding how to clinically test vascular-based hypotheses for the
treatment of AD will be discussed, including recent imaging advances for monitoring disease progression.
Moreover, emerging science on molecular and physiological processes that can be leveraged as targets for
novel therapeutics will be presented. This symposium will fill an important gap in the conference landscape,
presenting a focused, in-depth discussion on the synergies between AD and vascular disease research,
building upon the recently defined need to better understand neurovascular dysregulation in AD and vascular
dementia (36). This landmark event will unite 200 in-person basic, translational, and clinical researchers —
along with a global audience of Webinar participants — from academia, industry, government, and non-profit
organizations, working on neurodegenerative disorders and vascular disease in an effort to understand,
prevent, and treat AD and vascular dementias such as small vessel disease (SVD). Sessions will address
5 central aims: (i) Elucidate the relationship between genetic information and neurovascular pathology in AD
and SVD; (ii) Explore novel molecular targets and physiological processes critical to vascular function and CNS
health, using human studies and animal models; (iii) Describe clinical aspects of neurovascular dysregulation
and inflammation in AD and SVD and identify biomarkers for vascular-based mechanisms; (iv) Identify
knowledge gaps and future research required for breakthroughs in prevention and treatment of AD; and (v)
Showcase and encourage the participation of Early-Career, female, and Underrepresented Minority
investigators via short talks, poster presentations and prizes, travel fellowships, and discounted registration.
In addition, the NINDS’ specific goal of disseminating information will be met through a simulcast Webinar
and publication of an enduring open-access Academy eBriefing. A collaborative, multidisciplinary
approach will be critical to meeting the urgent unmet need for AD patients. To that end, this event will
consider new disease mechanisms and therapeutic targets for AD, from a broad range of perspectives.
阿尔茨海默病被视为一种神经血管炎症性疾病
项目摘要/摘要
阿尔茨海默病是一种毁灭性的神经退行性疾病,缺乏有效的治疗方法。多数
检验长期存在的阿尔茨海默病淀粉样蛋白假说的临床试验显示前景渺茫。小说的未来
针对该病其他病理生理过程的治疗尚不确定。越来越多的证据
支持神经血管炎症作为AD发病和加重的主要原因或加重因素的作用
进步。然而,科学界还没有给AD贴上血管疾病的标签,问题仍然存在
关于神经血管炎症作为潜在治疗靶点的可行性。为了解决这一争议
迎头赶上,纽约科学院将举办为期一天的研讨会并同时转播网络研讨会,
“阿尔茨海默病被视为一种神经血管炎症性疾病”,2016年12月6日。这样做的目的是
研讨会的目的是评估临床和临床前数据,调查神经血管病理学在
AD的发展。理解如何在临床上检验基于血管的假说的关键障碍
将讨论AD的治疗,包括监测疾病进展的最新成像进展。
此外,关于分子和生理过程的新兴科学可以被用作
将介绍新的治疗方法。这次研讨会将填补会议格局中的一个重要空白,
对AD和血管疾病研究之间的协同作用进行有重点的、深入的讨论,
建立在最近确定的需要的基础上,更好地了解AD和血管的神经血管失调
痴呆(36例)。这一里程碑式的活动将团结200名面对面的基础、翻译和临床研究人员-
以及来自学术界、工业界、政府和非营利组织的全球网络研讨会参与者
致力于神经退行性疾病和血管疾病的组织,以努力了解,
预防和治疗AD和血管性痴呆,如小血管疾病(SVD)。会议将解决
5个中心目标:(1)阐明遗传信息与阿尔茨海默病神经血管病理的关系
和SVD;(Ii)探索对血管功能和中枢神经系统至关重要的新的分子靶点和生理过程
健康,使用人体研究和动物模型;(3)描述神经血管失调的临床方面
AD和SVD中的炎症和识别血管机制的生物标志物;(Iv)识别
在预防和治疗阿尔茨海默病方面取得突破所需的知识差距和未来研究;以及(五)
展示和鼓励早期职业、女性和代表性不足的少数群体的参与
调查人员通过简短的谈话、海报介绍和奖品、旅行奖学金和折扣登记。
此外,还将通过联播网络研讨会实现NINDS传播信息的具体目标
并出版了一本经久不衰的开放获取学院eBriefing。协作、多学科
对于满足AD患者未得到满足的紧急需求,方法将是至关重要的。为此,本次活动将
从广泛的角度考虑AD的新的疾病机制和治疗目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Costantino Iadecola其他文献
Costantino Iadecola的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Costantino Iadecola', 18)}}的其他基金
ApoE4, neurovascular injury and cognitive impairment
ApoE4、神经血管损伤和认知障碍
- 批准号:
10419353 - 财政年份:2022
- 资助金额:
$ 1.5万 - 项目类别:
High-speed imaging of cortical and white matter microvascular flow in AD/ADRD models
AD/ADRD 模型中皮质和白质微血管血流的高速成像
- 批准号:
10523289 - 财政年份:2022
- 资助金额:
$ 1.5万 - 项目类别:
ApoE4, Neurovascular Injury and Cognitive Impairment
ApoE4、神经血管损伤和认知障碍
- 批准号:
10593979 - 财政年份:2022
- 资助金额:
$ 1.5万 - 项目类别:
ApoE4 and mechanisms of diffuse white matter injury
ApoE4 与弥漫性白质损伤的机制
- 批准号:
9756482 - 财政年份:2016
- 资助金额:
$ 1.5万 - 项目类别:
ApoE4 and mechanisms of diffuse white matter injury
ApoE4 与弥漫性白质损伤的机制
- 批准号:
9355719 - 财政年份:2016
- 资助金额:
$ 1.5万 - 项目类别:
ApoE4 and mechanisms of diffuse white matter injury
ApoE4 与弥漫性白质损伤的机制
- 批准号:
9264693 - 财政年份:2016
- 资助金额:
$ 1.5万 - 项目类别:
Dietary sodium, neurovascular dysfunction and cerebrovascular risk
膳食钠、神经血管功能障碍和脑血管风险
- 批准号:
10298081 - 财政年份:2015
- 资助金额:
$ 1.5万 - 项目类别:
Dietary Sodium, Neurovascular Dysfunction and Cerebrovascular Risk
膳食钠、神经血管功能障碍和脑血管风险
- 批准号:
10650322 - 财政年份:2015
- 资助金额:
$ 1.5万 - 项目类别:
相似海外基金
REU Site: Summer Academy in Sustainable Manufacturing
REU 网站:可持续制造夏季学院
- 批准号:
2348993 - 财政年份:2024
- 资助金额:
$ 1.5万 - 项目类别:
Standard Grant
The European Hydrogen Academy (HyAcademy.EU)
欧洲氢学院 (HyAcademy.EU)
- 批准号:
10110448 - 财政年份:2024
- 资助金额:
$ 1.5万 - 项目类别:
EU-Funded
GP-UP Ocean Research College Academy Engagement in Authentic Geoscience Learning Ecosystems (ORCA-EAGLE)
GP-UP 海洋研究学院学院参与真实的地球科学学习生态系统 (ORCA-EAGLE)
- 批准号:
2326962 - 财政年份:2024
- 资助金额:
$ 1.5万 - 项目类别:
Standard Grant
HyAcademy.EU: The European Hydrogen Academy
HyAcademy.EU:欧洲氢学院
- 批准号:
10101978 - 财政年份:2024
- 资助金额:
$ 1.5万 - 项目类别:
EU-Funded
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 1.5万 - 项目类别:
Operating Grants
Conference: Cyberinfrastructure Leadership Academy: Team Science and Grand Challenges
会议:网络基础设施领导学院:团队科学和重大挑战
- 批准号:
2414440 - 财政年份:2024
- 资助金额:
$ 1.5万 - 项目类别:
Standard Grant
Travel: NSF Student Travel Grant for 2024 Academy of Management Annual Meeting (AOM)
旅行:2024 年管理学院年会 (AOM) 的 NSF 学生旅行补助金
- 批准号:
2420866 - 财政年份:2024
- 资助金额:
$ 1.5万 - 项目类别:
Standard Grant
Semiconductor Higher Technical Skills Academy Wales: Recruitment, Retention & Upskilling
威尔士半导体高等技术技能学院:招聘、保留
- 批准号:
10076049 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Collaborative R&D
Simulation Academy at Yale: Youth Entering Science (SAY-YES!)
耶鲁大学模拟学院:青年进入科学(说是!)
- 批准号:
10663646 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Collaborative Research: GP-GO: Climate Leaders Academy: a professional development opportunity in the geosciences
合作研究:GP-GO:气候领袖学院:地球科学领域的专业发展机会
- 批准号:
2232215 - 财政年份:2023
- 资助金额:
$ 1.5万 - 项目类别:
Continuing Grant














{{item.name}}会员




